Intech Investment Management LLC Buys 18,274 Shares of Vericel Corporation $VCEL

Intech Investment Management LLC increased its stake in shares of Vericel Corporation (NASDAQ:VCEL) by 51.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,533 shares of the biotechnology company’s stock after acquiring an additional 18,274 shares during the quarter. Intech Investment Management LLC owned about 0.11% of Vericel worth $2,389,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Captrust Financial Advisors lifted its position in Vericel by 3.4% during the 4th quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company’s stock valued at $336,000 after purchasing an additional 199 shares during the period. State of Wyoming increased its stake in Vericel by 3.8% during the 1st quarter. State of Wyoming now owns 10,428 shares of the biotechnology company’s stock worth $465,000 after purchasing an additional 381 shares in the last quarter. Portside Wealth Group LLC grew its stake in shares of Vericel by 9.9% during the 1st quarter. Portside Wealth Group LLC now owns 6,546 shares of the biotechnology company’s stock worth $292,000 after acquiring an additional 591 shares in the last quarter. CW Advisors LLC grew its stake in shares of Vericel by 0.3% during the 1st quarter. CW Advisors LLC now owns 182,866 shares of the biotechnology company’s stock worth $8,159,000 after acquiring an additional 593 shares in the last quarter. Finally, US Bancorp DE grew its stake in shares of Vericel by 29.9% during the 1st quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 706 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Stephens reaffirmed an “overweight” rating and set a $67.00 price target on shares of Vericel in a research note on Monday, June 16th. Canaccord Genuity Group decreased their price target on shares of Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 1st. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Vericel presently has an average rating of “Buy” and a consensus price target of $60.40.

Vericel Price Performance

VCEL stock opened at $31.42 on Tuesday. The company has a fifty day moving average price of $36.54 and a two-hundred day moving average price of $40.67. Vericel Corporation has a one year low of $30.26 and a one year high of $63.00. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of 261.86 and a beta of 1.33.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The company had revenue of $63.24 million during the quarter, compared to the consensus estimate of $64.61 million. During the same quarter last year, the firm earned ($0.10) earnings per share. The company’s revenue was up 20.1% on a year-over-year basis. Research analysts anticipate that Vericel Corporation will post 0.14 EPS for the current fiscal year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.